ALGS

$1.32

Aligos Therapeutics

ALGS

Earnings Whisper ®

N/A

1st Quarter March 2023

Consensus: ($0.47)

Revenue: N/A

Thursday

Jun 8

4:05 PM ET

Score

Grade

Tweet Share Watch

Tweet Share Watch

Latest EPS

Thursday, March 9, 2023

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results

What do you expect when ALGS reports earnings?

Beat

Meet

Miss

Where is ALGS's stock price going from here?

Flat

Down

Analysts

Score

Grade

Sentiment

Analysts

Pivots

Resistance

$1.49

$1.42

$1.37

$1.30

Support

$1.25

$1.18

$1.13

Trends

Short-term Price

Intermediate-term Price

Long-term Price

Investors' Sentiment

Analysts' Sentiment

Earnings Estimates

Growth

Description

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is focused on the development of antiviral therapies for chronic hepatitis B and coronaviruses as well as liver diseases. Aligos Therapeutics, Inc. is based in SAN FRANCISCO, Calif.